Business Wire

The Next Evolution of the JOST KKS Automatic Coupling System: the KKS-U Connector

16.5.2023 11:00:00 EEST | Business Wire | Press release

Share

In April 2021 JOST introduced the revolutionary KKS automatic coupling system. It enables the driver to couple and uncouple the semi-trailer via remote control – automatically, safely and quickly. Climbing out of the cabin, cranking down the landing gear and manually connecting the spiral cable, air and brake connections are all a thing of the past. Now JOST presents the latest development of the KKS: the KKS-U Connector which is retrofittable to existing trailers that already are on the roads of this world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The KKS-U Connector is easily retrofittable to trailers that are already in use. (Photo: JOST)

Coupling and uncoupling a trailer is still a lengthy, expensive and hazardous procedure. The truck driver has to be aware of many different things, each of which are time-consuming and pose a hazard to health and safety. As the global market leader for fifth wheel couplings and landing gears, JOST is providing a smart solution for the future of coupling with its KKS automatic coupling system. The KKS 42 fifth wheel coupling, Modul E-Drive electric landing gear, sensor coupling system, 3-sensors, LubeTronic automatic lubrication system, KKS remote control and the ISO 13044-2-certified KKS connector all combine to form an innovative system for the coupling process.

KKS-U Connector retrofittable to existing trailers

Until now the KKS was a solution for mixed fleets and new trailers. JOST has now further developed the system and is introducing the new KKS-U Connector to the market. Fitted to the underside of the trailer, the KKS-U Connector is an alternative installation variant and enables fleet operators to equip existing trailers easily with the KKS. It connects all the mechanical, electric, and air connections between the truck and trailer, eliminating the need for the standard vulnerable air, electrics and ABS/EBS spiral lines.

The KKS-U basically consists of three parts: the reliable future-proof and ISO 13044-2 compliant standard wedge, the steel spring and the cable box. The newly designed wedge has the familiar KKS connector installed inside. It is attached to the high-quality JOST king pin and rotates around it when cornering. The steel spring encases the supply lines for air, brake and electric safely and reliably. The supply lines are safely stowed in the KKS cable box and are fed into the steel spring when cornering.

“The KKS-U Connector is a unique solution for all trailers that are already in operation. Due to a particularly straightforward installation, they can be effortlessly equipped with the KKS system. No modifications to the trailer chassis are necessary”, said Andreas Jakubin, Product Manager KKS. “Thus, the KKS-U contributes to further savings in time and expenses as well as avoidance of accidents.”

Advantages of the KKS: more efficiency and safety for truck drivers

Using the KKS automatic coupling system can cut the time required to change a trailer by up to 50 percent, as there is no need to manually crank the landing gear, connect the supply lines or open the fifth wheel coupling. The KKS significantly reduces the total costs for each circuit, with savings of up to 50 percent possible during the coupling and uncoupling process. It is particularly well suited for transport companies which perform coupling processes often and drive short distances, such as those in on-site transport, as the time saved here really pays off financially. Another application is the transport of goods where safety plays a key role, such as hazardous goods, as the sensor monitoring guarantees a high level of security against trailer losses and incorrect coupling. The KKS is also an ideal solution for transport between production sites and logistics facilities. Errors or damage caused during the coupling process are eliminated completely thanks to monitoring through the KKS remote control. For example, the Modul E-Drive landing gear is always fully retracted automatically. Moreover, the KKS reduces the probability of trailer losses due to erroneous operation, damage and occupational accidents to virtually zero.

Furthermore, the KKS makes all the physically demanding tasks of the coupling process a thing of the past, as well as ensuring that this process is no longer dependent on the weather or time of day and significantly reducing stress. A standard pneumatic cylinder opens the fifth wheel coupling effortlessly, even when the tractor-trailer is twisted. The automatic coupling process means that the driver does not have to climb in and out of the cab as often, nor climb onto the catwalk between truck and semi-trailer – two factors that significantly reduce the potential for injury. These benefits mean the KKS opens new possibilities for a more diverse driver pool; as such, JOST is providing an answer to demographic change and the lack of specialist workers.

More information on the KKS and KKS-U Connector online at: kks-futurenow.com

About JOST:

JOST is a world-leading producer and supplier of safety-critical systems for the commercial vehicle industry. Under the umbrella brand of JOST, the comprehensive range of products is broken down into systems for applications on the road and in agriculture:

The JOST brand includes fifth wheel couplings, landing gears, ball bearing turntables, king pins and container locks as well as components for alternating systems. Truck and trailer axles are also sold under the JOST brand. The tradition-steeped ROCKINGER brand comprises the core components of towing hitches, drawbar eyes and drawbars for transporters and trucks. TRIDEC offers steering systems and axle suspensions for trailers.

ROCKINGER products are also used in agricultural applications. Quicke has been part of the JOST family since February 2020 and specialises in agricultural front loaders and equipment.

JOST currently employs over 3,600 staff worldwide and has sales and production sites in over 20 countries and on all five continents. JOST has been listed on the Frankfurt Stock Exchange. Further information on JOST can be found here: www.jost-world.com

Press images can be found here: https://www.jost-world.com/en/corporate/mediacenter/press-releases.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christin Zindritsch
Manager Marketing Communications
christin.zindritsch@jost-world.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye